Cargando…

Efficacy and safety of Telitacicept in patients with IgA nephropathy

Detalles Bibliográficos
Autores principales:	Liang, Dongrui, Li, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10626081/ https://www.ncbi.nlm.nih.gov/pubmed/37936774 http://dx.doi.org/10.12669/pjms.39.6.8393

Ejemplares similares

Role of telitacicept in the treatment of IgA nephropathy
por: Wu, Lijun, et al.
Publicado: (2023)

Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria
por: Lv, Jicheng, et al.
Publicado: (2022)

Telitacicept for autoimmune nephropathy
por: Cai, Jingjing, et al.
Publicado: (2023)

A new promising biological agent for refractory lupus nephritis: Telitacicept
por: Liu, Shuangyan, et al.
Publicado: (2023)

IgA nephropathy with podocytic infolding glomerulopathy
por: Wang, Zhouyang, et al.
Publicado: (2023)

IgA nephropathy preceded by erythroderma with eosinophilia
por: Takatsu, Mina, et al.
Publicado: (2022)

Serum IgA-Fibronectin Concentration and IgA Nephropathy Diagnosis in Adults With Glomerulonephritis: A Diagnostic Test Study
por: Suhail, Sufi M.
Publicado: (2021)

Case report: Successful treatment of refractory membranous nephropathy with telitacicept
por: Zhang, Lei, et al.
Publicado: (2023)

Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review
por: Chen, Youyuan, et al.
Publicado: (2014)

The Role of IgA in the Pathogenesis of IgA Nephropathy
por: Perše, Martina, et al.
Publicado: (2019)

Safety Evaluation of COVID-19 Vaccine in Patients With IgA Nephropathy or IgA Vasculitis Nephritis
por: Zan, Jincan, et al.
Publicado: (2022)

IgA nephropathy with leucocytoclastic vasculitis
por: Wei, Lin-Yan, et al.
Publicado: (2018)

Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
por: Du, Bing, et al.
Publicado: (2017)

IgA Vasculitis and IgA Nephropathy: Same Disease?
por: Pillebout, Evangeline
Publicado: (2021)

Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study
por: Jin, Hui-Zhi, et al.
Publicado: (2023)

Experimental IgA nephropathy
Publicado: (1979)

Sulodexide in IgA nephropathy
Publicado: (2013)

T lymphocytes in IgA nephropathy
por: Tang, Yuyan, et al.
Publicado: (2020)

Serum IgA, IgM, and IgG responses in COVID-19
por: Ma, Huan, et al.
Publicado: (2020)

Secondary IgA Nephropathy Shares the Same Immune Features With Primary IgA Nephropathy
por: Wang, Manliu, et al.
Publicado: (2019)

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy
por: Papasotiriou, Marios, et al.
Publicado: (2022)

Efficacy and safety of calcineurin inhibitor treatment for IgA nephropathy: a meta-analysis
por: Song, Yu-Huan, et al.
Publicado: (2017)

IgG deposition in IgA nephropathy patients
por: Nasri, Hamid
Publicado: (2013)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
por: Nihei, Yoshihito, et al.
Publicado: (2023)

Efficacy and safety of tacrolimus-based treatment for non-rapidly progressive IgA nephropathy
por: Zhao, Lijuan, et al.
Publicado: (2023)

Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy
por: Chen, Pei, et al.
Publicado: (2018)

Efficacy and safety of sequential immunosuppressive treatment for severe IgA nephropathy: A retrospective study
por: Luo, Mian-Na, et al.
Publicado: (2023)

Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports
por: Tota, Maciej, et al.
Publicado: (2023)

IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank
por: Sukcharoen, Kittiya, et al.
Publicado: (2020)

Landscape of intestinal microbiota in patients with IgA nephropathy, IgA vasculitis and Kawasaki disease
por: Hu, Xueli, et al.
Publicado: (2022)

Vitamin D and hydroxychloroquine reduce renal injury and Ki67 expression in a rat model of IgA nephropathy via TLR4
por: Li, You, et al.
Publicado: (2021)

Tripterygium Wilfordii inhibits tonsillar IgA production by downregulating IgA class switching in IgA nephropathy
por: Li, Huining, et al.
Publicado: (2017)

Immunological abnormalities in patient with IgA nephropathy.
por: Ihm, C. G., et al.
Publicado: (1986)

Management of IgA Nephropathy in Pediatric Patients
por: Schroda, Sophie, et al.
Publicado: (2022)

Clinicopathologic comparisons of IgA nephropathy and IgA vasculitis nephropathy in children: a ten-year single-center experience
por: SU, QingXiao, et al.
Publicado: (2021)

IgA Nephropathy in a Patient with IgG Myeloma
por: Lakshmi, B. Sangeeta, et al.
Publicado: (2018)

Efficacy and safety of tacrolimus combined with glucocorticoid treatment for IgA nephropathy: a meta-analysis
por: Zhang, Yong, et al.
Publicado: (2018)

The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: A network meta-analysis
por: Tan, Jiaxing, et al.
Publicado: (2020)

Efficacy and Safety of Immunosuppressive Monotherapy Agents for IgA Nephropathy: A Network Meta-Analysis
por: Han, Shisheng, et al.
Publicado: (2021)

Efficacy and indications of tonsillectomy in patients with IgA nephropathy: a retrospective study
por: Li, Yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8c5a0rta3r0k4l0b44hh81o5g1